ESMO 2020 | BIONIKK: the first trial study in mccRCC

Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses results from the Phase II biomarker-driven BIONIKK trial (NCT02960906), investigating nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer patients. BIONIKK is the first trial to be conducted in metastatic clear cell renal carcinoma (mccRCC) to study the personalization of treatment with an immune checkpoint inhibitor (ICI) or TKI according to tumor molecular characteristics. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).